Susquehanna International Group’s TG Therapeutics TGTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$32.6M Sell
979,900
-76,600
-7% -$2.28M ﹤0.01% 1661
2025
Q4
$31.5M Buy
1,056,500
+270,900
+34% +$8.85M ﹤0.01% 1773
2025
Q3
$28.4M Buy
785,600
+110,000
+16% +$3.62M ﹤0.01% 1851
2025
Q2
$24.3M Sell
675,600
-176,700
-21% -$6.58M ﹤0.01% 1807
2025
Q1
$33.6M Sell
852,300
-145,500
-15% -$4.9M 0.01% 1289
2024
Q4
$30M Buy
997,800
+19,000
+2% +$545K ﹤0.01% 1533
2024
Q3
$22.9M Buy
978,800
+338,300
+53% +$7.39M ﹤0.01% 1696
2024
Q2
$11.4M Sell
640,500
-382,700
-37% -$6.11M ﹤0.01% 2321
2024
Q1
$15.6M Buy
1,023,200
+142,700
+16% +$2.27M ﹤0.01% 2064
2023
Q4
$15M Buy
880,500
+428,400
+95% +$4.98M ﹤0.01% 2122
2023
Q3
$3.78M Sell
452,100
-673,800
-60% -$9.39M ﹤0.01% 4003
2023
Q2
$28M Buy
1,125,900
+570,800
+103% +$14.7M 0.01% 1418
2023
Q1
$8.35M Sell
555,100
-142,200
-20% -$2.16M ﹤0.01% 2716
2022
Q4
$8.25M Buy
697,300
+333,400
+92% +$2.42M ﹤0.01% 2521
2022
Q3
$2.15M Buy
363,900
+2,600
+0.7% +$17.1K ﹤0.01% 4767
2022
Q2
$1.54M Buy
361,300
+73,500
+26% +$459K ﹤0.01% 5466
2022
Q1
$2.74M Buy
287,800
+170,600
+146% +$1.97M ﹤0.01% 4792
2021
Q4
$2.23M Buy
117,200
+37,400
+47% +$971K ﹤0.01% 5261
2021
Q3
$2.66M Buy
79,800
+72,400
+978% +$2.24M ﹤0.01% 5218
2021
Q2
$287K Sell
7,400
-98,000
-93% -$3.85M ﹤0.01% 10855
2021
Q1
$5.08M Sell
105,400
-292,200
-73% -$14M ﹤0.01% 3880
2020
Q4
$20.7M Sell
397,600
-23,200
-6% -$784K ﹤0.01% 1707
2020
Q3
$11.3M Sell
420,800
-40,900
-9% -$941K ﹤0.01% 2041
2020
Q2
$8.99M Sell
461,700
-433,200
-48% -$6.98M ﹤0.01% 2262
2020
Q1
$8.81M Buy
894,900
+133,700
+18% +$1.69M ﹤0.01% 1876
2019
Q4
$8.45M Buy
761,200
+366,800
+93% +$2.79M ﹤0.01% 2279
2019
Q3
$2.21M Sell
394,400
-305,200
-44% -$2.13M ﹤0.01% 3995
2019
Q2
$6.05M Buy
699,600
+81,300
+13% +$615K ﹤0.01% 2465
2019
Q1
$4.97M Buy
618,300
+362,600
+142% +$1.96M ﹤0.01% 2471
2018
Q4
$1.05M Sell
255,700
-72,400
-22% -$360K ﹤0.01% 4579
2018
Q3
$1.84M Sell
328,100
-240,500
-42% -$2.75M ﹤0.01% 4140
2018
Q2
$7.48M Buy
568,600
+122,000
+27% +$1.68M ﹤0.01% 2254
2018
Q1
$6.34M Buy
446,600
+93,100
+26% +$1.19M ﹤0.01% 2242
2017
Q4
$2.9M Buy
353,500
+4,800
+1% +$41.9K ﹤0.01% 3301
2017
Q3
$4.13M Buy
348,700
+239,000
+218% +$2.72M ﹤0.01% 2765
2017
Q2
$1.1M Sell
109,700
-110,200
-50% -$1.23M ﹤0.01% 5056
2017
Q1
$2.56M Buy
219,900
+208,700
+1,863% +$1.5M ﹤0.01% 3284
2016
Q4
$52K Buy
+11,200
New +$65.7K ﹤0.01% 9281
2016
Q2
Sell
-12,800
Closed -$109K 9315
2016
Q1
$109K Sell
12,800
-9,500
-43% -$83.1K ﹤0.01% 8394
2015
Q4
$266K Sell
22,300
-31,200
-58% -$394K ﹤0.01% 7917
2015
Q3
$539K Sell
53,500
-96,300
-64% -$1.43M ﹤0.01% 6975
2015
Q2
$2.48M Buy
149,800
+30,700
+26% +$486K ﹤0.01% 4238
2015
Q1
$1.84M Buy
119,100
+54,800
+85% +$830K ﹤0.01% 4476
2014
Q4
$1.02M Sell
64,300
-159,400
-71% -$2.08M ﹤0.01% 5840
2014
Q3
$2.39M Buy
223,700
+88,200
+65% +$818K ﹤0.01% 4296
2014
Q2
$1.27M Buy
135,500
+122,800
+967% +$785K ﹤0.01% 5542
2014
Q1
$88K Buy
+12,700
New +$75.2K ﹤0.01% 8598

Other funds holding TGTX

Susquehanna International Group's TGTX Position: Q1 2026 in Review

Susquehanna International Group reduced its TG Therapeutics (TGTX) stake by 39% in Q1 2026, selling an estimated $10.2M and leaving 544,720 shares worth $18.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2356.

Susquehanna International Group first reported a position in TGTX in Q2 2013 and has held it in 49 quarters since. The position peaked at $55.7M in Q2 2021. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

  • Susquehanna International Group held 544,720 shares of TG Therapeutics worth $18.1M as of Q1 2026.
  • Susquehanna International Group sold 342,731 TG Therapeutics shares in Q1 2026, an estimated $10.2M.
  • TG Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #2356 holding.
  • Susquehanna International Group first reported a position in TG Therapeutics in Q2 2013 and has held it in 49 quarters since.
  • Susquehanna International Group's TG Therapeutics position peaked at $55.7M in Q2 2021.
  • 363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.